IPO Databook: Scribe Therapeutics (SCTX US) - Jul 2026

207 Views17 Jul 2026 10:13

SUMMARY

Scribe Therapeutics Inc. is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies to extend healthy lifespan through disease prevention and durable therapeutic intervention.
Scribe's lead candidate STX-1150 is in a first-in-human trial, with initial data anticipated in H1 2027. The company also raised approximately $150.0 million in equity financing.
As of March 31, 2026, total assets were $65,208, and there is substantial doubt about the ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream